Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis

Inclusion Criteria: * Age 18-75 years * Body mass index (BMI) within the range 18 to 40 kg/m2 * Diagnosed with PsA for ≥6 months, and meeting Classification Criteria for Psoriatic Arthritis (CASPAR) at screening * Have active PsA: ≥3 tender joints and ≥3 swollen joints at screening and baseline and having hsCRP \>0.3 mg/dL (3 mg/L) * Having active plaque psoriasis (≥1 lesion ≥2cm) or nail psoriasis at screening * Biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) experienced participants can have received (a) up to one bDMARD (excluding TNF and IL-17 targeting therapies), and (b) up to one tsDMARD (excluding JAK targeting therapies) * bDMARD or tsDMARD naïve participants must have failed (a) at least one but no more than two csDMARDs AND/OR (b) Apremilast Exclusion Criteria: * Presence of other inflammatory or autoimmune conditions, including but not limited to rheumatoid arthritis, primary ankylosing spondylitis or non-radiographic axial spondyloarthritis without psoriasis, systemic lupus erythematosus, drug-induced dermatosis, inflammatory bowel disease, or Lyme disease * Current non-plaque forms of psoriasis (e.g., erythrodermic, guttate, or pustular psoriasis) * Use of \>10mg/day prednisone equivalent or change in oral glucocorticoid dosage within 4 weeks prior to Baseline * Received targeted intra-articular, trigger point, tender point, intra-bursa, or intra-tendon sheath surgical or pharmacological treatment within 8 weeks of the Screening Visit * Undergone surgical treatment for PsA including synovectomy and arthroplasty in more than 3 joints and/or within the last 12 weeks prior to the Screening Visit.